Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017134158) PSMA AND CD3 BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/134158 International Application No.: PCT/EP2017/052239
Publication Date: 10.08.2017 International Filing Date: 02.02.2017
IPC:
C07K 16/28 (2006.01) ,C07K 16/30 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
Applicants:
AMGEN RESEARCH (MUNICH) GMBH [DE/DE]; Staffelseestrasse 2 81477 Munich, DE
Inventors:
RAUM, Tobias; DE
MUENZ, Markus; DE
BROZY, Johannes; DE
KUFER, Peter; DE
HOFFMANN, Patrick; DE
FRIEDRICH, Matthias; DE
RATTEL, Benno; DE
BOGNER, Pamela; DE
WOLF, Andreas; DE
POMPE, Cornelius; DE
Agent:
WEINZIERL, Gerhard; DE
KOCH, Andreas Dr.; DE
SCHIWECK, Wolfram Dr.; DE
Priority Data:
62/290,87503.02.2016US
Title (EN) PSMA AND CD3 BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS
(FR) CONSTRUCTIONS D'ANTICORPS IMPLIQUANT DES CELLULES T BISPÉCIFIQUES PSMA ET CD3
Abstract:
(EN) The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and the Macaca CD3 E chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
(FR) La présente invention concerne des constructions d'anticorps bispécifiques d'une modalité Fc spécifique caractérisées en ce qu'elles comprennent un premier domaine de liaison à PSMA, un deuxième domaine de liaison à un épitope extracellulaire de la chaîne E CD3 chez l'homme et le macaque, et un troisième domaine qui est la modalité Fc spécifique. L'invention concerne également un polynucléotide codant la construction d'anticorps, un vecteur comprenant ledit polynucléotide, des cellules hôtes exprimant ladite construction et une composition pharmaceutique les contenant.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
UAa201809048JP2017184723UY0001037105AR107582AU2017216237CA3011942
SG11201806150RMYPI 2018702683KR1020180101623IN201817028891ID2018/11114EP3411404
IL260920BR112018015415CN109311979EA201891753CR20180418PH1/2018/501558